Despite early Medicaid expansion, decreased durable virologic suppression among publicly insured people with HIV in Washington, DC: a retrospective analysis

Table 3 IOM standards of care among treatment-experienced DC Cohort participants, by insurance type and clinic type in Washington, DC, 2011–2015

	Total N(%)	Regular CD4 monitoring^a N(%)	P-value	Regular VL monitoring^b N(%)	P-value	Durable virologic suppression n^c N (%)	P-value
Insurance
Public	2537(68.2)	2154(84.9)	<.0001	2191(86.4)	<.0001	1760(69.4)	<.0001
Private	1186(31.8)	945(79.7)	<.0001	943(79.5)	<.0001	951(80.2)	<.0001
Site
Hospital-based	1513(40.6)	1222(80.8)	0.001	1211(80.1)	<.0001	1167(77.1)	<.0001
Community-based	2210(59.4)	1877(84.9)	0.001	1923(87.1)	<.0001	1544(69.8)	<.0001
*Siteinsurance**
Hospital-based/Public	601(39.7)	505(84.1)	0.009	499(83.1)	0.018	412(68.6)	<.0001
Hospital-based/Private	912(60.3)	717(78.6)	0.009	712(78.1)	0.018	755(82.8)	<.0001
Community-based/Public	1936(87.6)	1649(85.2)	0.417	1962(87.4)	0.151	1348(69.6)	0.574
Community-based/Private	274(12.4)	228(83.2)	0.417	231(84.3)	0.151	196(71.5)	0.574

Note: ART status was based on treatment status at study enrollment. P-values based on X²
^aRegular CD4 monitoring is defined as at least two CD4 lab measures 30 days apart in the 12 months following the index date
^bRegular VL monitoring is defined as at least two CD4 lab measures 30 days apart in the 12 months following the index date
^cDurable viral suppression is defined as last viral load < 50 copies/ML in the 12 months following the index date. Index date was defined as either the date of ART initiation or the date of study enrollment, whichever was the most recent

ISSN: 1471-2458